Genfit S.A. (OTCMKTS:GNFTF) Sees Significant Decline in Short Interest

Genfit S.A. (OTCMKTS:GNFTFGet Rating) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 4,000 shares, a decline of 28.6% from the April 30th total of 5,600 shares. Based on an average daily volume of 2,600 shares, the days-to-cover ratio is currently 1.5 days.

GNFTF opened at $5.00 on Friday. The business has a fifty day simple moving average of $5.00 and a 200 day simple moving average of $4.68. Genfit has a 1 year low of $3.37 and a 1 year high of $5.00.

Genfit Company Profile (Get Rating)

Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure.

Featured Stories

Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.